MAPT and Alzheimer disease: The current modalities utilized for tracking the progression of AD are principally reliant on imaging techniques – specifically, volumetric magnetic resonance imaging (MRI) [3] and positron emission tomography (PET) [4] – that facilitate the visual assessment of metabolically active or aggregated Aβ and tau within the brain, as well as cerebrospinal fluid (CSF) biomarkers indicative of Aβ42 and phosphorylated tau [5, 6].